Kymera Therapeutics Inc

17 sept 2026, 20:07 UTC

Kymera Therapeutics Inc is advancing during Thursday's market session, having reached a session high earlier before pulling back from that peak.

16 sept 2026, 20:10 UTC

Kymera Therapeutics Inc is trading higher as interest grows due to faster-than-expected enrollment in the Phase 2b BROADEN2 study for its drug KT-621.

15 sept 2026, 23:31 UTC

Kymera Therapeutics Inc shares are lower in after-market hours, continuing a four-session decline amid broader economic concerns from the NY Empire State Manufacturing Index drop.

11 sept 2026, 19:52 UTC

Kymera Therapeutics Inc is lower today, pulling back from earlier gains amid speculation about Federal Reserve interest rate hikes and broader market trends.

10 sept 2026, 20:07 UTC

Wolfe Research upgraded Kymera Therapeutics to Outperform, setting a price target of $180. Shares are trading higher amid increased investor interest.

9 sept 2026, 20:07 UTC

Kymera Therapeutics Inc shares are lower Wednesday, reflecting broader market pressures amid rising crude oil prices and inflation concerns.

8 sept 2026, 20:07 UTC

Kymera Therapeutics shares are lower amid insider selling, including a recent sale by Brian Adams. The stock has seen a cumulative decline since Friday.

2 sept 2026, 19:46 UTC

Shares rise as JPMorgan raises price target to $140.00.

28 ago 2026, 20:01 UTC

Kymera Therapeutics Inc shares are lower today, continuing a decline since Thursday. Trading volume is unusually high amid rising U.S. Treasury yields.

27 ago 2026, 20:02 UTC

Kymera Therapeutics Inc shares are lower today, diverging from recent gains amid high trading volume and broader market resilience following a drop in jobless claims.

25 ago 2026, 20:07 UTC

Kymera Therapeutics shares are higher today, supported by declining oil prices and lower Treasury yields, enhancing overall investor sentiment toward equities.

21 ago 2026, 19:26 UTC

Kymera Therapeutics Inc shares are lower during Friday's session despite earlier gains. Analysts maintain a consensus "Moderate Buy" rating with a target of $125.65.

20 ago 2026, 22:01 UTC

Kymera Therapeutics Inc. shares are higher in after-market trading, supported by a broader upward trend in biotechnology stocks. The price remains above its 20-day moving average.

19 ago 2026, 20:02 UTC

Kymera Therapeutics is rising amid gains in the ARK Genomic Revolution ETF, which increased significantly. The stock is also experiencing high market volume today.

18 ago 2026, 19:26 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier decline. No specific news was identified to explain the movement.

17 ago 2026, 19:54 UTC

Kymera Therapeutics Inc shares are trading higher today amid increased volume, maintaining a positive trend since Friday's close despite earlier intraday fluctuations.

14 ago 2026, 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12 ago 2026, 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6 ago 2026, 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5 ago 2026, 20:02 UTC

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4 ago 2026, 20:04 UTC

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3 ago 2026, 19:46 UTC

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31 jul 2026, 20:06 UTC

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30 jul 2026, 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29 jul 2026, 19:32 UTC

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28 jul 2026, 17:42 UTC

Shares lower despite Guggenheim's price target increase to $135.

27 jul 2026, 21:03 UTC

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24 jul 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 jul 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 jul 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.